All Releases
 |
Capstone Therapeutics Announces First Quarter 2009 Financial Results
May 11, 2009
|
18.3 KB |
|
| |
TEMPE, Ariz., May 11, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the first quarter 2009.
The Company reported a net loss of $4.1 million, or $0.10 per share, for the first quarter 2009, compared to a net loss of $2.7 m...
|
|
Capstone Therapeutics to Host Conference Call Discussing First Quarter 2009 Operating Results
May 6, 2009
|
15.5 KB |
|
| |
TEMPE, Ariz., May 6, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company") will host a conference call and webcast presenting first quarter 2009 operating results on May 11, 2009 at 4:30pm EDT / 3:30pm CDT / 1:30pm PDT. The call may be accessed at 888-211-7292 (domestic),...
|
|
Capstone Therapeutics Announces Publication of Second Data Group (Elevated Cholesterol) From Chrysalin(r) (TP508) Study Demonstrating Significant Benefit in a Pre-Clinical Model of Acute Heart Disease
Apr 22, 2009
|
19.9 KB |
|
| |
TEMPE, Ariz., Apr 22, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the second data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprot...
|
|
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Pilot Study in Keloid Scarring
Apr 3, 2009
|
15.9 KB |
|
| |
TEMPE, Ariz., Apr 3, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 pilot clinical trial in keloid scarring.
The Phase 2 pilot trial is a blinded, placebo controlled, multicenter, parallel group dose ranging study to evaluate the safety and prel...
|
|
Capstone Therapeutics Announces Publication of First Data Group From Chrysalin(r) (TP508) Study Demonstrating Significant Benefit in a Pre-Clinical Model of Acute Heart Disease
Mar 5, 2009
|
18.3 KB |
|
| |
TEMPE, Ariz., Mar 5, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) today announced publication of results from the first data group of a pre-clinical study demonstrating that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, showed a statistically significant cardioprotec...
|
|
Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today
Feb 10, 2009
|
16.8 KB |
|
| |
TEMPE, Ariz., Feb 10, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 clinical trial in dermal scarring.
The clinical trial is a Phase 2a double blind, placebo controlled, multi-center dose ranging study to evaluate the safety and preliminary eff...
|
|
Capstone Therapeutics to Host Investor Update Teleconference and Webcast February 10, 2009
Feb 5, 2009
|
15.5 KB |
|
| |
TEMPE, Ariz, Feb 5, 2009 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) will host a teleconference and webcast to discuss operating plans on Tuesday, February 10, 2009 at 4:30pm EST/ 3:30pm CST/ 2:30pm MST/ 1:30pm PST. The call may be accessed at 888-256-9134 (domestic), (+1) 913-312-1387 (international); accompanyin...
|
|
Capstone Therapeutics Announces Chrysalin(r) (TP508, Rusalatide Acetate) Scientific Abstracts to be Presented At the American Society for Cell Biology 48th Annual Meeting; Studies Characterize Integrin Interaction and Biologic Activity
Dec 15, 2008
|
16.2 KB |
|
| |
TEMPE, Ariz., Dec 15, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the publication of several abstracts characterizing the science of its novel thrombin peptide Chrysalin(r) (TP508 or rusalatide acetate). The abstracts being presented at the American Society for Cell Biology 48th Annual Meeting...
|
|
Capstone Therapeutics Announces Positive Safety Results in Primary Endpoint From Second AZX100 Phase 1 Clinical Trial in Dermal Scarring; Pharmacologic Signal Shown in Secondary Endpoints
Dec 10, 2008
|
16.4 KB |
|
| |
TEMPE, Ariz., Dec 10, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) announced today positive safety results were obtained in the second of two planned Phase 1 human clinical trials of AZX100 in dermal / hypertrophic scarring. No serious treatment-emergent adverse events were reported in any subject. Secondary o...
|
|
Capstone Therapeutics Announces Third Quarter 2008 Financial Results
Nov 6, 2008
|
19.3 KB |
|
| |
TEMPE, Ariz., Nov 6, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. (the "Company"), today announced financial results for the third quarter 2008.
The Company reported a net loss of $3.1 million, or $0.08 per share, for the third quarter 2008, compared to a net loss of $2.4 mi...
|
|
Capstone Therapeutics Receives NASDAQ Notice Temporarily Suspending Minimum Bid Price Rule
Oct 22, 2008
|
15.6 KB |
|
| |
TEMPE, Ariz., Oct 22, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS), trade name of OrthoLogic Corp. ("the Company"), received on August 11, 2008 a letter dated August 8, 2008 from The Nasdaq Stock Market notifying it that for the 30 consecutive business days preceding the date of the letter, the bid price of th...
|
|
Capstone Therapeutics to Present at Two Upcoming Conferences and to Host Conference Call Discussing Third Quarter 2008 Operating Results
Oct 14, 2008
|
16.6 KB |
|
| |
TEMPE, Ariz., Oct 14, 2008 (GlobeNewswire via COMTEX News Network) -- Capstone Therapeutics (Nasdaq:CAPS) is scheduled to make a presentation at the Seventh Annual BIO Investor Forum at 8:00am Wednesday, October 29, 2008 at the Palace Hotel in San Francisco, CA. The Company is also scheduled to make a presentation at the Rodman & Renshaw Annual Glo...
|
|
OrthoLogic Corp. Announces New Company Name: Capstone Therapeutics
Sep 30, 2008
|
11.3 KB |
|
| |
TEMPE, Ariz., Sep 30, 2008 (GlobeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that effective October 1, 2008, the Company will be known and doing business as Capstone Therapeutics. The new trading symbol on Nasdaq will be CAPS, and the company website will be www.capstonethx.com.
"The name Capstone was sel...
|
|
AZX100 Pre-Clinical Results Show Reduction of Fibrosis and Scarring; Human Clinical Safety Trials Continuing
Sep 12, 2008
|
11.7 KB |
|
| |
TEMPE, Ariz., Sep 12, 2008 (GlobeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from pre-clinical studies of AZX100 in the management of excessive dermal scarring. There are approximately 21 million surgical procedures performed annually in the U.S. that can result in some for...
|
|
Chrysalin (Rusalatide Acetate, TP508) Pre-Clinical Results Show Significant Beneficial Effect in Chronic Heart Disease
Sep 3, 2008
|
10.8 KB |
|
| |
TEMPE, Ariz., Sep 3, 2008 (GlobeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from a pre-clinical study of Chrysalin(r) (rusalatide acetate or TP508) in a model of chronic myocardial ischemia. The study demonstrates that Chrysalin significantly increases vascular perfusion an...
|
|
OrthoLogic Announces Completion of Dosing for Second AZX100 Phase 1 Human Clinical Trial in Dermal/Hypertrophic Scarring
Aug 14, 2008
|
10.5 KB |
|
| |
TEMPE, Ariz., Aug 14, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the completion of dosing for its second AZX100 Phase 1 human clinical trial in dermal/hypertrophic scarring. Patient follow-up is ongoing.
The clinical study is a Phase 1b placebo-controlled, single-center dose ranging study. The...
|
|
OrthoLogic to Present At Fourth Annual Noble Financial Equity Conference August 19, 2008
Aug 12, 2008
|
10.1 KB |
|
| |
TEMPE, Ariz., Aug 12, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) is scheduled to make a presentation at the Fourth Annual Noble Financial Equity Conference, Loews Lake Las Vegas Resort, Las Vegas, NV on August 19, 2008 at 1:00 pm PDT. Dana B. Shinbaum, Vice President, Business Development will provide an overview...
|
|
OrthoLogic Corp. Receives Nasdaq Notice Letter
Aug 11, 2008
|
10.6 KB |
|
| |
TEMPE, Ariz., Aug 11, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. ("the Company") received a letter from The Nasdaq Stock Market, dated August 8, 2008, notifying it that for the 30 consecutive business days preceding the date of the letter, the bid price of the Company's common stock had closed below the $1.00 per share minimum...
|
|
OrthoLogic Announces Second Quarter 2008 Financial Results
Aug 7, 2008
|
14.0 KB |
|
| |
TEMPE, Ariz., Aug 7, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) today announced financial results for the second quarter 2008.
OrthoLogic reported a net loss of $2.8 million, or $0.07 per share, for the second quarter 2008, compared to a net loss of $2.3 million or $0.06 per share for the second quarter 2007....
|
|
OrthoLogic Announces Chrysalin (TP508) Demonstrates Significant Benefit in a Pre-Clinical Model of Acute Heart Disease
Aug 7, 2008
|
10.4 KB |
|
| |
TEMPE, Ariz., Aug 7, 2008 (PrimeNewswire via COMTEX News Network) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today that Chrysalin(r) (rusalatide acetate or TP508), administered following the onset of ischemia, has shown a statistically significant benefit in a recently completed pre-clinical study designed to assess cardioprotective effects in a m...
|
|
|
